NCT05549401View on ClinicalTrials.gov

Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 29, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

December 9, 2022

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-348(4) F1

QD, PQ

DRUG

CKD-348(4) F2

QD, PQ

DRUG

CKD-828, D097, D337

QD, PQ

Trial Locations (1)

Unknown

H plus Yangji hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY